PLoS ONE (Jan 2015)

High Affinity Binders to EphA2 Isolated from Abdurin Scaffold Libraries; Characterization, Binding and Tumor Targeting.

  • Christopher Ullman,
  • Pascale Mathonet,
  • Arkadiusz Oleksy,
  • Agata Diamandakis,
  • Licia Tomei,
  • Anna Demartis,
  • Chiara Nardi,
  • Sonia Sambucini,
  • Antonino Missineo,
  • Karen Alt,
  • Christoph E Hagemeyer,
  • Matt Harris,
  • Amos Hedt,
  • Roland Weis,
  • Kurt R Gehlsen

DOI
https://doi.org/10.1371/journal.pone.0135278
Journal volume & issue
Vol. 10, no. 8
p. e0135278

Abstract

Read online

Abdurins are a novel antibody-like scaffold derived from the engineering of a single isolated CH2 domain of human IgG. Previous studies established the prolonged serum half-life of Abdurins, the result of a retained FcRn binding motif. Here we present data on the construction of large, diverse, phage-display and cell-free DNA display libraries and the isolation of high affinity binders to the cancer target, membrane-bound ephrin receptor tyrosine kinase class A2 (EphA2). Antigen binding regions were created by designing combinatorial libraries into the structural loops and Abdurins were selected using phage display methods. Initial binders were reformatted into new maturation libraries and low nanomolar binders were isolated using cell-free DNA display, CIS display. Further characterization confirmed binding of the Abdurins to both human and murine EphA2 proteins and exclusively to cell lines that expressed EphA2, followed by rapid internalization. Two different EphA2 binders were labeled with 64Cu, using a bifunctional MeCOSar chelator, and administered to mice bearing tumors from transplanted human prostate cancer cells, followed by PET/CT imaging. The anti-EphA2 Abdurins localized in the tumors as early as 4 hours after injection and continued to accumulate up to 48 hours when the imaging was completed. These data demonstrate the ability to isolate high affinity binders from the engineered Abdurin scaffold, which retain a long serum half-life, and specifically target tumors in a xenograft model.